NASDAQ:SNSS Sunesis Pharmaceuticals (SNSS) Stock Price, News & Analysis Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$2.38▼$5.3252-Week Range N/AVolume1.20 million shsAverage Volume4.33 million shsMarket Capitalization$96.26 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Sunesis Pharmaceuticals alerts: Email Address Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. About Sunesis Pharmaceuticals Stock (NASDAQ:SNSS)Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of targeted inhibitors for the treatment of hematologic and solid cancers. Its lead product candidate is vecabrutinib, a non-covalent inhibitor of Bruton's tyrosine kinase (BTK), which is in Phase 1b/2 clinical trial for the treatment of chronic lymphocytic leukemia, mantle cell lymphoma, and other B-cell malignancies. The company is also developing SNS-510, which is in preclinical pharmacology studies for the treatment of solid tumor and hematologic malignancies; various other partnered programs, such as TAK-580, a pan-Raf inhibitor program that is in Phase 1 clinical trial for the treatment of pediatric low-grade glioma; and vosaroxin, an anti-cancer quinolone derivative that intercalates DNA and inhibits topoisomerase II. It has a collaboration agreement with Biogen Idec MA, Inc. to discover, develop, and commercialize small molecule BTK inhibitors; and license agreement with Takeda Pharmaceutical Company Limited to develop and commercialize preclinical inhibitors of PDK1. Sunesis Pharmaceuticals, Inc. was founded in 1998 and is headquartered in South San Francisco, California.Read More Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. SNSS Stock News HeadlinesDecember 20, 2023 | seekingalpha.comAQSZF Aequus Pharmaceuticals Inc.August 6, 2022 | thestreet.com4 Breakout Stocks to Watch Going Into Labor DayJuly 27, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.January 14, 2022 | thestreet.com4 Stocks Under $10 to Trade NowSee More Headlines Receive SNSS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sunesis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/15/2020Today7/26/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:SNSS CUSIP86732860 CIK1061027 Webwww.sunesis.com Phone650-266-3500FaxN/AEmployees24Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($2.70) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-23,330,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-179.05% Return on Assets-72.27% Debt Debt-to-Equity RatioN/A Current Ratio7.74 Quick Ratio7.74 Sales & Book Value Annual Sales$2.07 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$1.42 per share Price / BookN/AMiscellaneous Outstanding Shares18,093,000Free FloatN/AMarket Cap$96.26 million OptionableOptionable Beta2.27 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report Key ExecutivesDr. Judith A. Fox (Age 64)Chief Scientific Officer and Exec. VP of R&D Comp: $562.19kMr. Parvinder S. Hyare (Age 50)Interim CEO & Principal Exec. Officer Ms. Tina Gullotta (Age 46)Principal Financial Officer, VP of Fin. & Principal Accounting Officer Dr. Deborah A. ThomasSr. VP, Regulatory Affairs, Quality Assurance & PharmacovigilanceMr. Daniel N. Swisher Jr. (Age 58)Strategic Advisor Key CompetitorsVanda PharmaceuticalsNASDAQ:VNDAXOMANASDAQ:XOMACodexisNASDAQ:CDXSRigel PharmaceuticalsNASDAQ:RIGLAchieve Life SciencesNASDAQ:ACHVView All Competitors SNSS Stock Analysis - Frequently Asked Questions How were Sunesis Pharmaceuticals' earnings last quarter? Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) announced its earnings results on Sunday, November, 15th. The biopharmaceutical company reported ($0.29) EPS for the quarter, topping analysts' consensus estimates of ($0.30) by $0.01. When did Sunesis Pharmaceuticals' stock split? Shares of Sunesis Pharmaceuticals reverse split on the morning of Thursday, September 3rd 2020. The 1-10 reverse split was announced on Wednesday, September 2nd 2020. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, September 2nd 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What is Dan Swisher Jr.'s approval rating as Sunesis Pharmaceuticals' CEO? 4 employees have rated Sunesis Pharmaceuticals Chief Executive Officer Dan Swisher Jr. on Glassdoor.com. Dan Swisher Jr. has an approval rating of 82% among the company's employees. What other stocks do shareholders of Sunesis Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Sunesis Pharmaceuticals investors own include Amarin (AMRN), QUALCOMM (QCOM), NVIDIA (NVDA), VBI Vaccines (VBIV) and Inovio Pharmaceuticals (INO). This page (NASDAQ:SNSS) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | Sponsored4 Steps to Survive the Coming Market CrashCracks threaten us with a widespread collapse unlike anything we've seen in our lifetime. During this prese...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sunesis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sunesis Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
